- Home
- PLG vs ACHV Comparison
PLG vs ACHV Comparison
Compare PLG & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PLG | ACHV |
|---|---|---|
| Founded | 2000 | N/A |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 250.1M | 239.0M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | PLG | ACHV |
|---|---|---|
| Price | $2.75 | $4.47 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $15.50 |
| AVG Volume (30 Days) | ★ 3.5M | 598.8K |
| Earning Date | 01-13-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.99 | $1.84 |
| 52 Week High | $3.36 | $5.78 |
Technical Indicators
Market Signals| Indicator | PLG | ACHV |
|---|---|---|
| Relative Strength Index (RSI) | 61.26 | 49.93 |
| Support Level | $2.45 | $4.23 |
| Resistance Level | $2.95 | $4.86 |
| Average True Range (ATR) | 0.22 | 0.26 |
| MACD | 0.02 | -0.04 |
| Stochastic Oscillator | 67.52 | 26.56 |
Price Performance
Historical ComparisonAbout PLG Platinum Group Metals Ltd. (Canada)
Platinum Group Metals Ltd is the operator of the Waterberg Project, a bulk underground PGM deposit located in South Africa. Waterberg was discovered by Platinum Group and is being jointly developed with Implats, the Japan Oil, Gas and Metals National Corporation (JOGMEC) and Hanwa Co. Ltd. Waterberg has the potential to be a large-scale, low-cost producer of palladium, platinum, rhodium, and gold. Geographically, it operates in Canada and South Africa.
About ACHV Achieve Life Sciences Inc.
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.